An Analysis of the Benefit of Using HEV Genotype 3 Antigens in Detecting Anti-HEV IgG in a European Population

• Annatina Schnegg,

  Affiliation Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland

  ⨯
• Philippe Bürgisser,

  Affiliation Services of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland

  ⨯
• Cyril André,

  Affiliation Services of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland

  ⨯
• Alain Kenfak-Foguena,

  Affiliation Infectious Diseases, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland

  ⨯
• Giorgia Canellini,

  Affiliation Service Régional Vaudois de Transfusion Sanguine, Epalinges, Switzerland

  ⨯
• Darius Moradpour,

  Affiliation Gastroenterology and Hepatology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland

  ⨯
• Florence Abravanel,

  Affiliation INSERM, U1043, Centre de Physiopathologie de Toulouse Purpan, Toulouse, and CHU Toulouse, Hôpital Purpan, Laboratoire de Virologie, Institut Fédératif de Biologie de Purpan, Toulouse, France

  ⨯
• Jacques Izopet,

  Affiliation INSERM, U1043, Centre de Physiopathologie de Toulouse Purpan, Toulouse, and CHU Toulouse, Hôpital Purpan, Laboratoire de Virologie, Institut Fédératif de Biologie de Purpan, Toulouse, France

  ⨯
• Matthias Cavassini ,

  Contributed equally to this work with: Matthias Cavassini, Katharine E. A. Darling

  Affiliation Infectious Diseases, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland

  ⨯
• Katharine E. A. Darling

  Contributed equally to this work with: Matthias Cavassini, Katharine E. A. Darling

  * E-mail: Katharine.Darling@chuv.ch

  Affiliation Infectious Diseases, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland

  ⨯